Independent. Sells nothing. Takes no clinic money.
Evidence reviewed July 2026 How we grade
Does Ibogaine Help?The evidence, graded Get updates
Safety

Is ibogaine safe?

Ibogaine is not casually safe. It has a real, well-established cardiac risk: it prolongs the QT interval and can trigger a potentially fatal arrhythmia. At least 33 deaths appear in the literature, mostly in unscreened or unmonitored settings. Proper screening and monitoring reduce that risk substantially but do not remove it.

The core danger: the heart

Ibogaine and its metabolite noribogaine block the hERG potassium channel in heart cells. That prolongs the QT interval on an ECG, which can set off torsades de pointes, a dangerous and sometimes fatal arrhythmia. This is not a fringe hypothesis: it is confirmed in human heart-cell studies and runs through essentially all the reported deaths.[1] It is the single most important fact about ibogaine safety, and every credible clinic builds its protocol around it.

What the death toll actually tells us

At least 33 ibogaine-associated deaths are documented in the scientific literature.[2] The pattern in those cases is as important as the number: most occurred in people with pre-existing heart disease, those taking other QT-prolonging or cardiac-active drugs, polydrug users, or people treated in settings with no cardiac monitoring or emergency capability. Deaths concentrate among opioid-dependent patients. In other words, the risk is real and it is also patterned and partly modifiable.

What reduces the risk

The 2016 clinical guidelines the field uses call for a specific stack of precautions: a pre-treatment 12-lead EKG reviewed for QT interval, electrolyte and liver testing, correcting potassium and magnesium beforehand, ACLS-trained staff and continuous cardiac monitoring during dosing, magnesium loading to protect against torsades, and supervision until the ECG normalizes. The Stanford veteran study used a magnesium protocol and reported no serious cardiac events, which is suggestive that these measures matter.[3] Newer multi-clinic data likewise reports lower mortality under modern screening than historical figures, though that data is largely self-reported.

What raises it

Skipping the EKG. Dosing someone with a long QT interval, low potassium or magnesium, or a QT-prolonging medication on board. Combining ibogaine with other cardiac-active or depressant drugs. Treating opioid-dependent patients without monitoring. And the underappreciated one: benzodiazepines, which ibogaine does not detox and which raise seizure risk on top of cardiac risk (see our benzodiazepine page).

What this means for you

  • The clinic's medical protocol is the product. An EKG before dosing is the floor, not a premium feature. A clinic that skips it is disqualifying.
  • Disclose every medication and heart-history detail honestly. The screening only protects you if it is accurate.
  • If you have heart disease, a long QT, or take QT-prolonging drugs, ibogaine may be contraindicated for you. See our contraindications page.
  • Match the setting to your risk: opioid detox and any cardiac history demand a medical-tier clinic with monitoring, not a retreat.

Reviewed against primary literature and updated July 2026. This is information, not medical advice.

New research, explained honestly

When a trial reports, a policy shifts, or the evidence changes, we send a short plain-language briefing. About once a month. We store only your email, and every message has an unsubscribe link.